A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma
The primary objective of this study is to estimate the time to progressive disease for patients with advanced hepatocellular cancer who receive LY2181308.
Hepatocellular Carcinoma
DRUG: LY2181308
Phase 1: Determine recommended dose, every cycle|Phase 2: Time to progression, baseline to measured progressive disease
Phase 1: Safety, every cycle|Phase 2: Overall Survival, Baseline to date of death from any cause|Phase 2: Response rate, Baseline to measured PD|Phase 2: Pharmacokinetics, Cycle 1 and Cycle 2|Phase 2: Safety, every cycle
The primary objective of this study is to estimate the time to progressive disease for patients with advanced hepatocellular cancer who receive LY2181308.